159 related articles for article (PubMed ID: 10929038)
1. The polyneuropathy associated with Waldenström's macroglobulinaemia can be treated effectively with chemotherapy and the anti-CD20 monoclonal antibody rituximab.
Weide R; Heymanns J; Köppler H
Br J Haematol; 2000 Jun; 109(4):838-41. PubMed ID: 10929038
[TBL] [Abstract][Full Text] [Related]
2. Induction of complete haematological remission after monotherapy with anti-CD20 monoclonal antibody (RITUXIMAB) in a patient with alkylating agent resistant Waldenström's macroglobulinaemia.
Weide R; Heymanns J; Köppler H
Leuk Lymphoma; 1999 Dec; 36(1-2):203-6. PubMed ID: 10613467
[TBL] [Abstract][Full Text] [Related]
3. Myelopathy from Waldenström's macroglobulinemia: improvement after Rituximab therapy.
Liberato B; Riethmuller A; Comenzo RL; Lis E; Raizer JJ
J Neurooncol; 2003 Jun; 63(2):207-11. PubMed ID: 12825826
[TBL] [Abstract][Full Text] [Related]
4. Successful treatment of diffuse large B-cell lymphoma following Waldenström's macroglobulinemia with CHOP chemotherapy followed by combination therapy of CHOP with rituximab.
Uchino K; Sameshima H; Miyamoto T; Iino T; Kato K; Henzan H; Aoki K; Nagafuji K; Gondo H; Harada M
Intern Med; 2004 Feb; 43(2):131-4. PubMed ID: 15005256
[TBL] [Abstract][Full Text] [Related]
5. Extended rituximab therapy for previously untreated patients with Waldenström's macroglobulinemia.
Dimopoulos MA; Zervas C; Zomas A; Hamilos G; Gika D; Efstathiou E; Panayiotidis P; Vervessou E; Anagnostopoulos N; Christakis J
Clin Lymphoma; 2002 Dec; 3(3):163-6. PubMed ID: 12521393
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy in Waldenstrom's macroglobulinemia: preliminary evidence of clinical activity.
Byrd JC; White CA; Link B; Lucas MS; Velasquez WS; Rosenberg J; Grillo-López AJ
Ann Oncol; 1999 Dec; 10(12):1525-7. PubMed ID: 10643548
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Waldenström's macroglobulinemia with rituximab.
Dimopoulos MA; Zervas C; Zomas A; Kiamouris C; Viniou NA; Grigoraki V; Karkantaris C; Mitsouli C; Gika D; Christakis J; Anagnostopoulos N
J Clin Oncol; 2002 May; 20(9):2327-33. PubMed ID: 11981004
[TBL] [Abstract][Full Text] [Related]
8. Rituximab-based treatments in Waldenström's macroglobulinemia.
Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
[TBL] [Abstract][Full Text] [Related]
9. Effects of rituximab on a patient with Waldenström's macroglobulinaemia with deletion 13q14.
Mori A; Tamaru J; Kondo H
Eur J Haematol; 2002; 69(5-6):321-3. PubMed ID: 12460239
[TBL] [Abstract][Full Text] [Related]
10. IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.
Yang Y; Canepa C
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33622752
[TBL] [Abstract][Full Text] [Related]
11. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia.
Treon SP; Branagan AR; Hunter Z; Santos D; Tournhilac O; Anderson KC
Ann Oncol; 2004 Oct; 15(10):1481-3. PubMed ID: 15367407
[TBL] [Abstract][Full Text] [Related]
12. Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma.
Hensel M; Villalobos M; Kornacker M; Krasniqi F; Ho AD
Clin Lymphoma Myeloma; 2005 Sep; 6(2):131-5. PubMed ID: 16231851
[TBL] [Abstract][Full Text] [Related]
13. [Effective treatment with rituximab in two patients with Waldenström macroglobulinemia].
Yoshimi A; Arai S; Iijima K; Iki S; Usuki K; Urabe A
Rinsho Ketsueki; 2005 Oct; 46(10):1109-13. PubMed ID: 16440772
[TBL] [Abstract][Full Text] [Related]
14. Ofatumumab: another way to target CD20 in Waldenström's macroglobulinaemia?
Buske C
Lancet Haematol; 2017 Jan; 4(1):e4-e5. PubMed ID: 27914970
[No Abstract] [Full Text] [Related]
15. Extended rituximab therapy in Waldenström's macroglobulinemia.
Treon SP; Emmanouilides C; Kimby E; Kelliher A; Preffer F; Branagan AR; Anderson KC; Frankel SR;
Ann Oncol; 2005 Jan; 16(1):132-8. PubMed ID: 15598950
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin M 'Flare' after rituximab-associated acute tubular necrosis in Waldenström's macroglobulinemia.
Izzedine H; Bourry E; Amrouche L; Brocheriou I; Uzunov M; Capron F; Leblond V; Deray G
Int J Hematol; 2009 Mar; 89(2):218-222. PubMed ID: 19156501
[TBL] [Abstract][Full Text] [Related]
17. Treatment of plasma cell dyscrasias by antibody-mediated immunotherapy.
Treon SP; Shima Y; Preffer FI; Doss DS; Ellman L; Schlossman RL; Grossbard ML; Belch AR; Pilarski LM; Anderson KC
Semin Oncol; 1999 Oct; 26(5 Suppl 14):97-106. PubMed ID: 10561024
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic experience of Bing-Neel Syndrome associated with Waldenstrom's macroglobulinemia.
Kim HD; Shin KC; Cho HS; Kim MK; Lee KH; Hyun MS
J Korean Med Sci; 2007 Dec; 22(6):1079-81. PubMed ID: 18162727
[TBL] [Abstract][Full Text] [Related]
19. Waldenstrom's macroglobulinaemia: to treat or not to treat?
Sundriyal D; Kumar N; Kotwal S; Shirsi N
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25414220
[TBL] [Abstract][Full Text] [Related]
20. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
